Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208561 | 0.88 | FYN (0.47) | HSD17B10SMN1; SMN2HPGDTP53BP1L3MBTL1 | |
| SCHEMBL1366312 | 0.87 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AMRGPRX4FYN | |
| SCHEMBL12475742 | 0.84 | HDAC8 (0.45) | SMN1; SMN2POLBHPGDHTTL3MBTL1 | |
| SCHEMBL9893361 | 0.80 | LOXL2 (0.42) | SMN1; SMN2POLBALDH1A1KMT2A | |
| SCHEMBL13571463 | 0.79 | RXRA (0.40) | HSD17B10SMN1; SMN2POLBHPGDKMT2A | |
| SCHEMBL5083356 | 0.78 | HPGD (0.51) | HSD17B10SMN1; SMN2POLBHPGDHTT | |
| SCHEMBL15192320 | 0.77 | ATM (0.46) | HSD17B10SMN1; SMN2HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL3319225 | 0.72 | SMN1; SMN2 (0.65) | HSD17B10SMN1; SMN2POLBHPGDHTT | |
| SCHEMBL1015209 | 0.71 | ALDH1A1 (0.45) | HSD17B10SMN1; SMN2POLBL3MBTL1ALDH1A1 | |
| SCHEMBL3766770 | 0.71 | CYP1A2 (0.45) | HSD17B10POLBHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | DPP4, DPP3, DPP7 | HSD17B10 872/4885SMN1; SMN2 2612/4885POLB 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.